BioSpace News Archive

Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the second quarter ended June 30, 2023, and recent corporate highlights.

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson’s disease, Parkinson’s-related disorders and other diseases of the Abelson Tyrosine Kinases, reported financial results for the second quarter ended June 30, 2023 and highlighted recent developments.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today provided a business update and financial results for the quarter ended June 30, 2023.

Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today reported financial results for the third quarter ended June 30, 2023.

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the second quarter ended June 30, 2023.

BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the three months ended June 30, 2023, and reported on recent corporate developments.

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, announced results for the first quarter of fiscal year 2024 ended June 30, 2023.

Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition” (ACI), or the “Company”) is pleased to announced the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application No. 17/575,025, titled “Solid Forms of ALPHA-1062 Gluconate,” which includes claims covering protection for crystalline solid forms of ALPHA-1062 and will bolster existing patents that the company holds.

Scientific Industries, Inc., a life sciences tool provider and a developer of digitally simplified bioprocessing products, yesterday reported financial results for the three and six month periods ended June 30, 2023.

ProMIS Neurosciences Inc. (Nasdaq: PMN) today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update.